SCHEMBL1977058

SCHEMBL1977058

Cc1cc(=O)n(Cc2ncco2)c(C)c1C(=O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
PARG Q86W56 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
GRIN1 Q05586 1/20 0.32
KCNH2 Q12809 1/20 0.32
GRIN2B Q13224 1/20 0.32
S1PR3 Q99500 3/20 0.32
CCR9 P51686 1/20 0.32
KDM4E B2RXH2 3/20 0.32
CYP1B1 Q16678 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9947645 0.78 CYP1B1 (0.34) PTGDR2CYP1B1
SCHEMBL1367105 0.72 CYP1B1 (0.39) PTGDR2S1PR3CYP1B1MEN1KMT2A
SCHEMBL1976987 0.70 KDM4E (0.40) ALDH1A1MAPK1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL2314611 0.68 CYP1A2 (0.36) PTGDR2CYP1A2CYP2C9CYP2C19GRIN1
SCHEMBL21826182 0.64 ALDH1A1 (0.48) ALDH1A1MAPK1SMN1; SMN2KDM4EMEN1
SCHEMBL9947686 0.63 ALDH1A1 (0.43) ALDH1A1MAPK1SMN1; SMN2KDM4EMEN1
SCHEMBL13401691 0.60 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL9947675 0.60 LDHA (0.38) ALDH1A1MAPK1SMN1; SMN2CYP1A2CYP2C9
SCHEMBL14436537 0.60 KDM4E (0.45) ALDH1A1MAPK1KDM4EMEN1KMT2A
SCHEMBL3564058 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207347-B2 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-06-26 US disclosed
US-8207347-B2 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-06-26 US disclosed
US-8207347-B2 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-06-26 US disclosed
WO-2011072691-A1 PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-06-23 WO disclosed
US-20110144164-A1 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2011-06-16 US disclosed
US-20110144164-A1 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2011-06-16 US disclosed
US-20110144164-A1 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144164-A1 Pyridone derivatives as NK3 antagonists KCNK3, GRIK3, KCND3 ALDH1A1 2028/4885MAPK1 2115/4885SMN1; SMN2 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.